Clindamycin Phosphate Topical Solution recalled due to defective container leakage
Contract Pharmaceuticals Limited Canada is recalling Clindamycin Phosphate Topical Solution 1% due to defective containers with slow leakage. Lot 119874 (expires 06/30/2025) distributed nationwide in the U.S. and Puerto Rico is affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. The hazard is a container defect affecting product integrity, which represents a theoretical risk rather than documented harm.
Plain-English summary
Contract Pharmaceuticals Limited Canada is recalling Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottles due to defective containers. The containers are out of specification for weight as a result of slow leakage discovered at the 12-month stability testing timepoint.
The affected product is Lot #119874 with an expiration date of 06/30/2025, manufactured for Glasshouse Pharmaceuticals Limited Canada. The recall covers 11,750 bottles distributed nationwide in the United States and Puerto Rico.
Consumers who have this product should contact their healthcare provider or pharmacist for guidance. Do not use the product without consulting a medical professional.
The recalled product
- Product
- Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottle, Manufactured for: Glasshouse Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, L5N 6R8, NDC 71428-0003-60
- Manufacturer
- Contract Pharmaceuticals Limited Canada
- Category
- Drug — Topical Solution
- Hazard
- container-defect
- leakage
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 119874
- Exp 06/30/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27